The relationship between incretin-based medications and gallbladder disease has gained attention following post-marketing surveillance and real-world data
A., Jezzard, P., Hennessy, T
Clinical studies consistently show that Semaglutide not only facilitates significant weight loss but also offers additional health benefits such as improved cardiovascular risk factors and better blood sugar control
This difference stems from the added GIPR activation, which enhances glucose metabolism and reduces hunger through a complementary mechanism
Since GLP-1 inhibitors have a half-life of about five weeks, it can take a few months for them to be fully cleared
The UKs drug watchdog, NICE, has recommended that semaglutide be used to treat patients who have a body mass index (BMI) of more than 27 and established cardiovascular disease